Role of angiotensin-converting-enzyme inhibitors in the treatment of hypertension

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Therapeutic goals for the treatment of hypertension and the ability of various angiotensin-converting-enzyme (ACE) inhibitors to meet these goals are presented. The 1997 Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure ONC-VI) does not recommend ACE inhibitors for first-line therapy in the treatment of hypertension; however, these guidelines do identify compelling indications for ACE inhibitor therapy, including diabetes mellitus (type 1) with proteinuria, heart failure, or previous myocardial infarction with systolic dysfunction. Since the JNC-Vl guidelines were developed, the results of a prospective randomized clinical trial in patients with uncomplicated hypertension have demonstrated that ACE inhibitor therapy is as effective as conventional treatment in the prevention of cardiovascular morbidity and mortality. In hypertensive patients with diabetes, therapy with captopfil, enalapfil, fosinophi, or ramipril has resulted in significant reductions in cardiovascular events. In addition, tight blood pressure control with an ACE inhibitor has resulted in a greater reduction in the risk of macrovascutar and microvascular complications of diabetes than was seen with less tight control. Recent study results support broader use of ACE inhibitors for hypertension than was recommended in the JNC-VI guidelines.

Original languageEnglish
JournalAmerican Journal of Health-System Pharmacy
Volume57
Issue number19 SUPPL. 1
StatePublished - Oct 1 2000

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Hypertension
Enzyme Therapy
Guidelines
Therapeutics
Ramipril
Aptitude
Diabetes Complications
Risk Reduction Behavior
Type 1 Diabetes Mellitus
Proteinuria
Randomized Controlled Trials
Heart Failure
Myocardial Infarction
Blood Pressure
Morbidity
Mortality

All Science Journal Classification (ASJC) codes

  • Leadership and Management
  • Pharmaceutical Science

Cite this

Role of angiotensin-converting-enzyme inhibitors in the treatment of hypertension. / Hilleman, Daniel E.

In: American Journal of Health-System Pharmacy, Vol. 57, No. 19 SUPPL. 1, 01.10.2000.

Research output: Contribution to journalArticle

@article{c6b1f2785b2b4e5eafe5d840267570ae,
title = "Role of angiotensin-converting-enzyme inhibitors in the treatment of hypertension",
abstract = "Therapeutic goals for the treatment of hypertension and the ability of various angiotensin-converting-enzyme (ACE) inhibitors to meet these goals are presented. The 1997 Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure ONC-VI) does not recommend ACE inhibitors for first-line therapy in the treatment of hypertension; however, these guidelines do identify compelling indications for ACE inhibitor therapy, including diabetes mellitus (type 1) with proteinuria, heart failure, or previous myocardial infarction with systolic dysfunction. Since the JNC-Vl guidelines were developed, the results of a prospective randomized clinical trial in patients with uncomplicated hypertension have demonstrated that ACE inhibitor therapy is as effective as conventional treatment in the prevention of cardiovascular morbidity and mortality. In hypertensive patients with diabetes, therapy with captopfil, enalapfil, fosinophi, or ramipril has resulted in significant reductions in cardiovascular events. In addition, tight blood pressure control with an ACE inhibitor has resulted in a greater reduction in the risk of macrovascutar and microvascular complications of diabetes than was seen with less tight control. Recent study results support broader use of ACE inhibitors for hypertension than was recommended in the JNC-VI guidelines.",
author = "Hilleman, {Daniel E.}",
year = "2000",
month = "10",
day = "1",
language = "English",
volume = "57",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "19 SUPPL. 1",

}

TY - JOUR

T1 - Role of angiotensin-converting-enzyme inhibitors in the treatment of hypertension

AU - Hilleman, Daniel E.

PY - 2000/10/1

Y1 - 2000/10/1

N2 - Therapeutic goals for the treatment of hypertension and the ability of various angiotensin-converting-enzyme (ACE) inhibitors to meet these goals are presented. The 1997 Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure ONC-VI) does not recommend ACE inhibitors for first-line therapy in the treatment of hypertension; however, these guidelines do identify compelling indications for ACE inhibitor therapy, including diabetes mellitus (type 1) with proteinuria, heart failure, or previous myocardial infarction with systolic dysfunction. Since the JNC-Vl guidelines were developed, the results of a prospective randomized clinical trial in patients with uncomplicated hypertension have demonstrated that ACE inhibitor therapy is as effective as conventional treatment in the prevention of cardiovascular morbidity and mortality. In hypertensive patients with diabetes, therapy with captopfil, enalapfil, fosinophi, or ramipril has resulted in significant reductions in cardiovascular events. In addition, tight blood pressure control with an ACE inhibitor has resulted in a greater reduction in the risk of macrovascutar and microvascular complications of diabetes than was seen with less tight control. Recent study results support broader use of ACE inhibitors for hypertension than was recommended in the JNC-VI guidelines.

AB - Therapeutic goals for the treatment of hypertension and the ability of various angiotensin-converting-enzyme (ACE) inhibitors to meet these goals are presented. The 1997 Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure ONC-VI) does not recommend ACE inhibitors for first-line therapy in the treatment of hypertension; however, these guidelines do identify compelling indications for ACE inhibitor therapy, including diabetes mellitus (type 1) with proteinuria, heart failure, or previous myocardial infarction with systolic dysfunction. Since the JNC-Vl guidelines were developed, the results of a prospective randomized clinical trial in patients with uncomplicated hypertension have demonstrated that ACE inhibitor therapy is as effective as conventional treatment in the prevention of cardiovascular morbidity and mortality. In hypertensive patients with diabetes, therapy with captopfil, enalapfil, fosinophi, or ramipril has resulted in significant reductions in cardiovascular events. In addition, tight blood pressure control with an ACE inhibitor has resulted in a greater reduction in the risk of macrovascutar and microvascular complications of diabetes than was seen with less tight control. Recent study results support broader use of ACE inhibitors for hypertension than was recommended in the JNC-VI guidelines.

UR - http://www.scopus.com/inward/record.url?scp=0034307335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034307335&partnerID=8YFLogxK

M3 - Article

VL - 57

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 19 SUPPL. 1

ER -